Exicure, Inc. (NASDAQ:XCUR) Short Interest Update

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a large decrease in short interest in the month of March. As of March 13th, there was short interest totaling 58,790 shares, a decrease of 18.2% from the February 26th total of 71,837 shares. Currently, 2.0% of the shares of the company are short sold. Based on an average daily trading volume, of 15,085 shares, the days-to-cover ratio is presently 3.9 days.

Exicure Trading Down 3.4%

NASDAQ XCUR traded down $0.15 during trading hours on Tuesday, hitting $4.32. 7,764 shares of the company’s stock traded hands, compared to its average volume of 32,597. Exicure has a 52 week low of $3.10 and a 52 week high of $14.11. The firm has a market capitalization of $27.52 million, a P/E ratio of -5.61 and a beta of 4.13. The business’s fifty day moving average price is $4.30 and its two-hundred day moving average price is $4.68.

Exicure (NASDAQ:XCUR) last released its quarterly earnings results on Wednesday, March 25th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($18.60) by $18.14.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Exicure in a research note on Monday, December 29th. Wall Street Zen raised Exicure to a “hold” rating in a report on Saturday, January 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.